Jiawei Zhang
Tingting Liu2
Zhongzhi Jia- 1Department of Interventional and Vascular Surgery, The Third Affiliated Hospital of Nanjing Medical University (Changzhou Second People’s Hospital), Changzhou, China
- 2Graduate College of Dalian Medical University, Dalian, China
- 3Department of Interventional Radiology, Huaian Hospital of Huai’an City (Huaian Cancer Hospital), Huai’an, China
A Corrigendum on
Paricalcitol alleviates intestinal ischemia-reperfusion injury via inhibition of the ATF4-CHOP pathway
by Zhang J, Liu T, Xue T, Jia Z (2025). Front Pharmacol. 16:1529343. doi: 10.3389/fphar.2025.1529343
In the published article, there were errors in Figures 5C, 6C. Due to Authors’ oversight during figure preparation, the ATF4 and β-actin image that was originally intended for Figure 2C was mistakenly placed again in Figure 5C. Additionally, in Figure 6C, the TUNEL and DAPI staining images for the siATF4 group were incorrectly inserted. The authors also replaced the ATF4 and β-actin images in Figure 6, as the originally selected images were not sufficiently representative of the observed trends. The corrected Figures 5, 6 and its caption appear below.
Figure 5. Paricalcitol mitigates hypoxia-reoxygenation (H/R) injury in IEC-6 cells (A) Representative TUNEL staining (green) and nuclear staining (blue) results and apoptosis analysis of IEC-6 cells (scale bar = 100 μm; n = 6 in each group). (B) Differences in IEC-6 cell viability among groups assessed using the cell counting kit-8 assay (n = 6 in each group). (C) Western blot analysis and densitometric quantification of vitamin D receptor (VDR), activating transcription factor 4 (ATF4), and C/EBP homologous protein (CHOP) expression levels in IEC-6 cells (n = 6 in each group). Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. All data are presented as mean ± SD. *, P values <0.05; **, P values <0.01; ***, P values <0.001; ****, P values <0.0001.
Figure 6. Silencing vitamin D receptor (VDR) abolished the protective effect of paricalcitol in IEC-6 cells (A)The effect of siVDR treatment on cell viability assessed using cell counting kit-8 assay in IEC-6 cells (n = 6 in each group). (B) Western blot analysis and densitometric quantification of VDR, ATF4, and CHOP expression levels in IEC-6 cells after siVDR treatment (n = 6 in each group). (C) Representative TUNEL staining (green) and nuclear staining (blue) results for IEC-6 cells after siVDR treatment (scale bar = 200 μm; n = 6 in each group). Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc test. All data are presented as mean ± SD. *, P values <0.05; **, P values <0.01; ***, P values <0.001; ****, P values <0.0001.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: intestinal, ischemia reperfusion injury, paricalcitol, ATF4, CHOP, VDR (vitamin D receptor)
Citation: Zhang J, Liu T, Xue T and Jia Z (2025) Corrigendum: Paricalcitol alleviates intestinal ischemia-reperfusion injury via inhibition of the ATF4-CHOP pathway. Front. Pharmacol. 16:1632205. doi: 10.3389/fphar.2025.1632205
Received: 20 May 2025; Accepted: 16 June 2025;
Published: 25 June 2025.
Edited and reviewed by:
Daniele Maria-Ferreira, Instituto de Pesquisa Pelé Pequeno Príncipe, BrazilCopyright © 2025 Zhang, Liu, Xue and Jia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tongqing Xue, dmg2Mzc2QDE2My5jb20=; Zhongzhi Jia, amlhemhvbmd6aGkuMTk5OEAxNjMuY29t